Literature DB >> 3005397

Decreased natural killer activity in thalassemia major: a possible consequence of iron overload.

A N Akbar, P A Fitzgerald-Bocarsly, M de Sousa, P J Giardina, M W Hilgartner, R W Grady.   

Abstract

We have investigated the natural killer (NK) activity of both fractionated (Percoll density gradient) and unfractionated mononuclear cells from patients with beta-thalassemia major who are iron overloaded as a consequence of chronic transfusion therapy. These patients were found to have significantly decreased NK activity against K562 targets at all effector:target ratios tested (p less than 0.001). Both splenectomized and nonsplenectomized patients had normal proportions of Leu-11b-staining (NK) cells. Since they had normal to elevated absolute white cell and lymphocyte counts, a change in the absolute number of NK cells could not account for the decreased killing. We also found that the decrease in NK activity was transfusion related (r = -0.603, p less than 0.005). To determine whether or not this decrease in NK activity could be related to iron overload, we preincubated patient effector cells with desferrioxamine (DFO) or 2,3-dihydroxybenzoic acid (DHB) for 6 hr before addition of K562 targets. Both of these iron-chelating agents consistently increased the NK activity of cells from thalassemia patients. DHB had the greater effect, being able to increase patient NK activity to virtually normal levels. On the other hand, preincubation of cells from normal controls with DHB caused only a slight increase in NK activity, while similar treatment with DFO had little or no effect. When target cells were preincubated with the chelating agents before addition of either normal or patient effector cells, no change in cytotoxicity was seen, demonstrating that the chelating agents act at the effector cell level. Furthermore, if the chelating agents were saturated with iron prior to preincubation with the effectors, no increase in the cytotoxicity of thalassemic NK cells was observed. These results indicate that thalassemia patients have a reversible, transfusion-related decrease in NK function which may arise as a consequence of iron overload.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005397

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Immune cell functions in iron overload.

Authors:  M de Sousa
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantation.

Authors:  A N Akbar; P L Amlot; A Timms; G Lombardi; R Lechler; G Janossy
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Characterization of circulating CD4+ CD8+ double positive and CD4- CD8- double negative T-lymphocyte in children with β-thalassemia major.

Authors:  Asmaa M Zahran; Khaled Saad; Khalid I Elsayh; Mohamd A Alblihed
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

4.  Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.

Authors:  Robert S Nickel; Ifeyinwa Osunkwo; Aneesah Garrett; Jennifer Robertson; David R Archer; Daniel E L Promislow; John T Horan; Jeanne E Hendrickson; Leslie S Kean
Journal:  Br J Haematol       Date:  2015-03-05       Impact factor: 6.998

Review 5.  The role of iron and iron binding proteins in lymphocyte physiology and pathology.

Authors:  J D Kemp
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

6.  Influence of low dietary iron and iron overload on urethan-induced lung tumors in mice.

Authors:  F O Omara; B R Blakley
Journal:  Can J Vet Res       Date:  1993-07       Impact factor: 1.310

7.  Modulation of the defective natural killer activity seen in thalassaemia major with desferrioxamine and alpha-interferon.

Authors:  A N Akbar; P A Fitzgerald-Bocarsly; P J Giardina; M W Hilgartner; R W Grady
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

8.  Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection.

Authors:  N Arber; M Moshkowitz; F Konikoff; Z Halpern; A Hallak; M Santo; E Tiomny; M Baratz; T Gilat
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

9.  Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.

Authors:  Bianca Maria Ricerca; Arturo Di Girolamo; Deborah Rund
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-28       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.